Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
Persistent viral infection with viral reservoirs and detection of circulating spike protein after the initial acute illness is one potential pathogenic mechanism for Long COVID. This mechanism may be able to be targeted by SARS-CoV-2 monoclonal antibodies (mAbs). This trial will study the safety and efficacy of AER002 to treat individuals with Long COVID in an adult population.
Epistemonikos ID: 7742222f54a5bc14b9ffa7f388a13845a3e167e4
First added on: May 27, 2023